Ruxolitinib As a Steroid-Sparing Treatment for Chronic Graft Vs Host Disease: A Case Series

Key Points

• Improvement in symptoms observed in chronic graft vs host disease patients receiving ruxolitinib therapy, particularly those with steroid resistance.
• Partial or complete responses were noted in the majority of cases, highlighting ruxolitinib’s potential as an effective treatment.
• Observational analysis of multiple cases provides insights into the effectiveness and safety of ruxolitinib as a treatment.
• Further studies are needed to confirm these findings, as this case series only includes a limited number of treatments.